logo
  

Immune Design Corp. (IMDZ) Is Rising On FDA Feedback

Immune Design Corp. (IMDZ) announced after the close Monday that it plans to initiate a Phase 3 trial for CMB305 based on discussions it held with the FDA. The stock is now up 0.90 on 4K shares.

Immune Design declined throughout the first half of Monday's session and closed down by 0.85 at $10.10. The stock fell to nearly a 3-week low.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

Inflation data from the U.S. garnered maximum attention this week on the economics front, along with the interest rate decision by the European Central Bank. Read our stories to find out how these two key events are set to influence monetary policy in the months ahead. Other main news from the U.S. were the release of the minutes of the latest Fed policy session and the jobless claims data. Elsewhere, the interest rate decision by the Bank of Canada was also in focus.

View More Videos
Follow RTT